Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling

PLoS Computational Biology

Volumn 12, Issue 3, 2016, Pages

  Jacobs, Matthieu ^a   Grégoire, Nicolas ^a   Couet, William ^a   Bulitta, Jurgen B ^b  

^a INSERM   (France)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; DRUG DOSAGE; DYNAMICS; INTELLIGENT SYSTEMS; MICROORGANISMS; PARAMETER ESTIMATION; POPULATION STATISTICS;

ANTIMICROBIAL DRUG; BACTERIAL POPULATION; DRUG DEVELOPMENT; DYNAMIC CONDITION; IN-VITRO; INFECTION MODELS; MECHANISTICS; PHARMACODYNAMIC MODELS; PHARMACOKINETIC PHARMACODYNAMIC MODELS; RESISTANCE MECHANISMS;

MONTE CARLO METHODS;

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM; BOOTSTRAPPING; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; MATHEMATICAL MODEL; MEASUREMENT PRECISION; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; STATISTICAL BIAS; BIOLOGICAL MODEL; COMPARATIVE STUDY; COMPUTER SIMULATION; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PHARMACOKINETICS; PHYSIOLOGY; STATISTICAL MODEL;

ANTI-BACTERIAL AGENTS; BACTERIA; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACOKINETICS;

EID: 84962082064     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004782     Document Type: Article

References (46)

1. Andrews JM, Determination of minimum inhibitory concentrations. The Journal of antimicrobial chemotherapy. 2001;48Suppl 1:5–16. 11420333
2. Craig WA, Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10; quiz 1–2. 9455502
3. Czock D, Keller F, Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn. 2007;34(6):727–51. 17906920
4. Mueller M, de la Pena A, Derendorf H, Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrobial agents and chemotherapy. 2004;48(2):369–77. 14742182
5. Chung P, McNamara PJ, Campion JJ, Evans ME, Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(9):2957–65. 16940088
6. Gregoire N, Raherison S, Grignon C, Comets E, Marliat M, Ploy MC, et al. Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54(6):2379–84. doi: 10.1128/AAC.01478-0820368392
7. Bulitta JB, Landersdorfer CB, Forrest A, Brown SV, Neely MN, Tsuji BT, et al. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Current pharmaceutical biotechnology. 2011;12(12):2044–61. Epub 2011/05/11. 21554212
8. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2006;50(9):2946–50. Epub 2006/08/31. 16940086
9. Moya B, Dotsch A, Juan C, Blazquez J, Zamorano L, Haussler S, et al. Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS pathogens. 2009;5(3):e1000353. Epub 2009/03/28. doi: 10.1371/journal.ppat.100035319325877
10. Nielsen EI, Viberg A, Lowdin E, Cars O, Karlsson MO, Sandstrom M, Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother. 2007;51(1):128–36. Epub 2006/10/25. 17060524
11. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL, Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55(5):601–7. 15772142
12. Craig WA, Choosing an antibiotic on the basis of pharmacodynamics. Ear, nose, & throat journal. 1998;77(6 Suppl):7–11; discussion -2.
13. Gloede J, Scheerans C, Derendorf H, Kloft C, In vitro pharmacodynamic models to determine the effect of antibacterial drugs. The Journal of antimicrobial chemotherapy. 2010;65(2):186–201. doi: 10.1093/jac/dkp43420026612
14. Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, D'Hondt RE, et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother. 2010;54(5):2051–62. Epub 2010/03/10. doi: 10.1128/AAC.00881-0920211900
15. Schmidt S, Rock K, Sahre M, Burkhardt O, Brunner M, Lobmeyer MT, et al. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrobial agents and chemotherapy. 2008;52(11):3994–4000. doi: 10.1128/AAC.00427-0818779351
16. Yano Y, Oguma T, Nagata H, Sasaki S, Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci. 1998;87(10):1177–83. 9758673
17. Bulitta JB, Ly NS, Landersdorfer CB, Wanigaratne NA, Velkov T, Yadav R, et al. Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. Antimicrob Agents Chemother. 2015;59(4):2315–27. Epub 2015/02/04. doi: 10.1128/AAC.04099-1425645838
18. Campion JJ, McNamara PJ, Evans ME, Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2005;49(1):209–19. 15616298
19. Katsube T, Yano Y, Yamano Y, Munekage T, Kuroda N, Takano M, Pharmacokinetic-pharmacodynamic modeling and simulation for bactericidal effect in an in vitro dynamic model. J Pharm Sci. 2008;97(9):4108–17. Epub 2008/03/05. doi: 10.1002/jps.2126518314887
20. Meagher AK, Forrest A, Dalhoff A, Stass H, Schentag JJ, Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob Agents Chemother. 2004;48(6):2061–8. Epub 2004/05/25. 15155200
21. Nielsen EI, Cars O, Friberg LE, Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother. 2011;55(4):1571–9. doi: 10.1128/AAC.01286-1021282424
22. Schmidt S, Sabarinath SN, Barbour A, Abbanat D, Manitpisitkul P, Sha S, et al. Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(12):5039–45. Epub 2009/09/30. doi: 10.1128/AAC.00633-0919786607
23. Liu P, Rand KH, Obermann B, Derendorf H, Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents. 2005;25(2):120–9. Epub 2005/01/25. 15664481
24. Mouton JW, Vinks AA, Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet. 2005;44(2):201–10. 15656698
25. Spicknall IH, Foxman B, Marrs CF, Eisenberg JN, A modeling framework for the evolution and spread of antibiotic resistance: literature review and model categorization. American journal of epidemiology. 2013;178(4):508–20. Epub 2013/05/11. doi: 10.1093/aje/kwt01723660797
26. Zhi JG, Nightingale CH, Quintiliani R, Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. Journal of pharmacokinetics and biopharmaceutics. 1988;16(4):355–75. Epub 1988/08/01. 3193364
27. Mouton JW, Vinks AA, Punt NC, Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother. 1997;41(4):733–8. 9087479
28. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003;112(2):275–85. Epub 2003/07/17. 12865415
29. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL, Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis. 2004;190(9):1642–51. 15478070
30. Jusko W, A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents. Journal of pharmacokinetics and biopharmaceutics. 1973;1:175–200.
31. Tam VH, Kabbara S, Vo G, Schilling AN, Coyle EA, Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(8):2626–31. 16870751
32. Hocquet D, Vogne C, El Garch F, Vejux A, Gotoh N, Lee A, et al. MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrobial agents and chemotherapy. 2003;47(4):1371–5. Epub 2003/03/26. 12654672
33. Yadav R, Landersdorfer CB, Nation RL, Boyce JD, Bulitta JB, Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59(4):2286–98. Epub 2015/02/04. doi: 10.1128/AAC.04379-1425645842
34. de la Pena A, Grabe A, Rand KH, Rehak E, Gross J, Thyroff-Friesinger U, et al. PK-PD modelling of the effect of cefaclor on four different bacterial strains. Int J Antimicrob Agents. 2004;23(3):218–25. 15164961
35. Treyaprasert W, Schmidt S, Rand KH, Suvanakoot U, Derendorf H, Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents. 2007;29(3):263–70. 17194570
36. Nikolaou M, Tam VH, A new modeling approach to the effect of antimicrobial agents on heterogeneous microbial populations. Journal of mathematical biology. 2006;52(2):154–82. 16195922
37. Bulitta JB, Ly NS, Yang JC, Forrest A, Jusko WJ, Tsuji BT, Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(1):46–56. Epub 2008/10/15. doi: 10.1128/AAC.00489-0818852268
38. Bauer RJ, Guzy S, Ng C, A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J. 2007;9(1):E60–83. Epub 2007/04/06. 17408237
39. Bulitta JB, Landersdorfer CB, Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J. 2011;13(2):212–26. Epub 2011/03/05. doi: 10.1208/s12248-011-9258-921374103
40. Bulitta JB, Bingolbali A, Shin BS, Landersdorfer CB, Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. Aaps J. 2011;13(2):201–11. doi: 10.1208/s12248-011-9257-x21369876
41. Beal SL, Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481–504. 11768292
42. Nielsen EI, Friberg LE, Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. Pharmacological reviews. 2013;65(3):1053–90. Epub 2013/06/28. doi: 10.1124/pr.111.00576923803529
43. Drusano GL, Liu W, Brown DL, Rice LB, Louie A, Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus. J Infect Dis. 2009;199(2):219–26. Epub 2008/12/04. doi: 10.1086/59573919049435
44. Ly NS, Bulitta JB, Rao GG, Landersdorfer CB, Holden PN, Forrest A, et al. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. J Antimicrob Chemother. 2015;70(5):1434–42. Epub 2015/02/26. doi: 10.1093/jac/dku56725712313
45. Louie A, Heine HS, Kim K, Brown DL, VanScoy B, Liu W, et al. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrobial agents and chemotherapy. 2008;52(7):2486–96. doi: 10.1128/AAC.01439-0718458134
46. Blaser J, Stone BB, Zinner SH, Two compartment kinetic model with multiple artificial capillary units. The Journal of antimicrobial chemotherapy. 1985;15Suppl A:131–7. 3980324